Close
Mark Jit

Professor of Vaccine Epidemiology

Education

Affiliations

Bio

Preferred Pronouns

Personal Academic Website

Research/Topics of Interest

Pathogens/Diseases of Main Interest/Expertise

COVID-19

Countries of Work/Collaboration

Projects

Papers

Toor J, Li X, Jit M, Trotter CL, Echeverria-Londono S, Hartner AM, Roth J, Portnoy A, Abbas K, Ferguson NM, Am Gaythorpe K. (2022). COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery. Vaccine

Gonçalves BP, Procter SR, Paul P, Chandna J, Lewin A, Seedat F, Koukounari A, Dangor Z, Leahy S, Santhanam S, John HB, Bramugy J, Bardají A, Abubakar A, Nasambu C, Libster R, Sánchez Yanotti C, Horváth-Puhó E, Sørensen HT, van de Beek D, Bijlsma MW, Gardner WM, Kassebaum N, Trotter C, Bassat Q, Madhi SA, Lambach P, Jit M, Lawn JE, , , , . (2022). Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. The Lancet. Global health

Vassall A, Sweeney S, Barasa E, Prinja S, Keogh-Brown MR, Tarp Jensen H, Smith R, Baltussen R, M Eggo R, Jit M. (2022). Integrating economic and health evidence to inform Covid-19 policy in low- and middle- income countries. Wellcome open research, (5)

Koltai M, Krauer F, Hodgson D, van Leeuwen E, Treskova-Schwarzbach M, Jit M, Flasche S. (2022). Determinants of RSV epidemiology following suppression through pandemic contact restrictions. Epidemics, (40)

Barnard RC, Davies NG, , Jit M, Edmunds WJ. (2022). Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. Nature communications, 13(1)

Wu D, Jin C, Bessame K, Tang FF, Ong JJ, Wang Z, Xie Y, Jit M, Larson HJ, Chantler T, Lin L, Gong W, Yang F, Jing F, Wei S, Cheng W, Zhou Y, Ren N, Qiu S, Bao J, Wen L, Yang Q, Tian J, Tang W, Tucker JD. (2022). Effectiveness of a pay-it-forward intervention compared with user-paid vaccination to improve influenza vaccine uptake and community engagement among children and older adults in China: a quasi-experimental pragmatic trial. The Lancet. Infectious diseases

Bosse NI, Abbott S, Bracher J, Hain H, Quilty BJ, Jit M, , van Leeuwen E, Cori A, Funk S. (2022). Comparing human and model-based forecasts of COVID-19 in Germany and Poland. PLoS computational biology, 18(9)

Koltai M, Warsame A, Bashiir F, Freemantle T, Reeve C, Williams C, Jit M, Flasche S, Davies NG, , Aweis A, Ahmed M, Dalmar A, Checchi F. (2022). Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. Wellcome open research, (6)

Winter AK, Lambert B, Klein D, Klepac P, Papadopoulos T, Truelove S, Burgess C, Santos H, Knapp JK, Reef SE, Kayembe LK, Shendale S, Kretsinger K, Lessler J, Vynnycky E, McCarthy K, Ferrari M, Jit M. (2022). Feasibility of measles and rubella vaccination programmes for disease elimination: a modelling study. The Lancet. Global health, 10(10)

Li X, Bilcke J, Vázquez Fernández L, Bont L, Willem L, Wisløff T, Jit M, Beutels P, . (2022). Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children. The Journal of infectious diseases

Bolotin S, Osman S, Hughes SL, Ariyarajah A, Tricco AC, Khan S, Li L, Johnson C, Friedman L, Gul N, Jardine R, Faulkner M, Hahné SJM, Heffernan JM, Dabbagh A, Rota PA, Severini A, Jit M, Durrheim DN, Orenstein WA, Moss WJ, Funk S, Turner N, Schluter W, Jawad JS, Crowcroft NS. (2022). In Elimination Settings, Measles Antibodies Wane Following Vaccination but Not Following Infection - A Systematic Review and Meta-Analysis. The Journal of infectious diseases

Echeverria-Londono S, Hartner AM, Li X, Roth J, Portnoy A, Sbarra AN, Abbas K, Ferrari M, Fu H, Jit M, Ferguson NM, Gaythorpe KAM. (2022). Exploring the subnational inequality and heterogeneity of the impact of routine measles immunisation in Africa. Vaccine

Markowitz LE, Drolet M, Lewis RM, Lemieux-Mellouki P, Perez N, Jit M, Brotherton JM, Ogilvie G, Kreimer AR, Brisson M. (2022). Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs. Vaccine

Liu Y, Pearson CAB, Sandmann FG, Barnard RC, Kim JH, , Flasche S, Jit M, Abbas K. (2022). Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. The Lancet regional health. Europe

Diamond C, Gong H, Sun FY, Liu Y, Quilty BJ, Jit M, Yang J, Yu H, Edmunds WJ, Baguelin M. (2022). Regional-based within-year seasonal variations in influenza-related health outcomes across mainland China: a systematic review and spatio-temporal analysis. BMC medicine, 20(1)

Leung K, Jit M, Leung GM, Wu JT. (2022). The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. The Lancet regional health. Western Pacific, (21)

Portnoy A, Hsieh YL, Abbas K, Klepac P, Santos H, Brenzel L, Jit M, Ferrari M. (2022). Differential health impact of intervention programs for time-varying disease risk: a measles vaccination modeling study. BMC medicine, 20(1)

Levin A, Boonstoppel L, Brenzel L, Griffiths U, Hutubessy R, Jit M, Mogasale V, Pallas S, Resch S, Suharlim C, Yeung KHT. (2022). WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. BMC medicine, 20(1)

Paternina-Caicedo A, Jit M, Alvis-Guzmán N, Fernández JC, Hernández J, Paz-Wilches JJ, Rojas-Suarez J, Dueñas-Castell C, Alvis-Zakzuk NJ, Smith AD, Hoz-Restrepo F. (2022). Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study. Lancet Regional Health. Americas, (12)

Burger E, Baussano I, Kim JJ, Laprise JF, Berkhof J, Schiller JT, Canfell K, Prem K, Brisson M, Jit M, Barnabas RV. (2022). Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions. Vaccine

Burger EA, Laprise JF, Sy S, Regan MC, Prem K, Jit M, Brisson M, Kim JJ. (2022). Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting. International journal of cancer

Sandmann FG, Tessier E, Lacy J, Kall M, Van Leeuwen E, Charlett A, Eggo RM, Dabrera G, Edmunds WJ, Ramsay M, Campbell H, Amirthalingam G, Jit M. (2022). Long-term health-related quality of life in non-hospitalised COVID-19 cases with confirmed SARS-CoV-2 infection in England: Longitudinal analysis and cross-sectional comparison with controls. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Kucharski AJ, Jit M, Logan JG, Cotten M, Clifford S, Quilty BJ, Russell TW, Peeling RW, Antonio M, Heymann DL. (2022). Travel measures in the SARS-CoV-2 variant era need clear objectives. Lancet

Van Trang N, Prem K, Toh ZQ, Viet Ha BT, Ngoc Lan PT, Tran HP, Pham QD, VAN Khuu N, Jit M, Luu DT, Khanh Ly LT, Cao V, LE-Ha TD, Bright K, Garland SM, Anh DD, Mulholland K. Prevalence and Determinants of Vaginal Infection With Human Papillomavirus Among Female University Students in Vietnam. In vivo (Athens, Greece), 36(1)

Chen Y, Li N, Lourenço J, Wang L, Cazelles B, Dong L, Li B, Liu Y, Jit M, Bosse NI, Abbott S, Velayudhan R, Wilder-Smith A, Tian H, Brady OJ, . (2022). Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. The Lancet. Infectious diseases

Tildesley MJ, Vassall A, Riley S, Jit M, Sandmann F, Hill EM, Thompson RN, Atkins BD, Edmunds J, Dyson L, Keeling MJ. (2022). Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study. Royal Society open science, 9(8)

Paul P, Chandna J, Procter SR, Dangor Z, Leahy S, Santhanam S, John HB, Bassat Q, Bramugy J, Bardají A, Abubakar A, Nasambu C, Libster R, Yanotti CS, Seedat F, Horváth-Puhó E, Hossain AKMT, Sadeq-Ur Rahman Q, Jit M, Newton CR, Milner K, Gonçalves BP, Lawn JE, . (2022). in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina. EClinicalMedicine, (47)

Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, Carter ED, Clark A, de Villiers MJ, Eilertson K, Ferrari MJ, Gamkrelidze I, Gaythorpe KAM, Grassly NC, Hallett TB, Hinsley W, Jackson ML, Jean K, Karachaliou A, Klepac P, Lessler J, Li X, Moore SM, Nayagam S, Nguyen DM, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Sy S, Tam Y, Tanvir H, Tran QM, Trotter CL, Truelove S, van Zandvoort K, Verguet S, Walker N, Winter A, Woodruff K, Ferguson NM, Garske T, . (2021). Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, 397(10272)

Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y. (2021). Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(12)

Prem K, Zandvoort KV, Klepac P, Eggo RM, Davies NG, , Cook AR, Jit M. (2021). Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. PLoS computational biology, 17(7)

Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. (2021). COVID-19 vaccine challenges: What have we learned so far and what remains to be done?. Health policy (Amsterdam, Netherlands)

Sandmann F, Jit M, Andrews N, Buckley HL, Campbell H, Ribeiro S, Sile B, Stowe J, Tessier E, Ramsay M, Amirthalingam G, Choi YH. (2021). Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis. Vaccine

Liu D, Leung K, Jit M, Wu JT. (2021). Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities. Vaccine

Turner HC, Archer RA, Downey LE, Isaranuwatchai W, Chalkidou K, Jit M, Teerawattananon Y. (2021). An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. Frontiers in public health, (9)

Hasso-Agopsowicz M, Lopman BA, Lanata CF, Rogawski McQuade ET, Kang G, Prudden HJ, Khalil I, Platts-Mills JA, Kotloff K, Jit M, Riddle MS, Pavlinac PB, Luz PM, Pitzer VE, Breiman RF, Giersing BK. (2021). World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens. Vaccine

Gaythorpe KAM, Abbas K, Huber J, Karachaliou A, Thakkar N, Woodruff K, Li X, Echeverria-Londono S, , Ferrari M, Jackson M, McCarthy K, Perkins AT, Trotter C, Jit M. (2021). Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. eLife, (10)

Wu JT, Mei S, Luo S, Leung K, Liu D, Lv Q, Liu J, Li Y, Prem K, Jit M, Weng J, Feng T, Zheng X, Leung GM. (2022). A global assessment of the impact of school closure in reducing COVID-19 spread. Philosophical transactions. Series A, Mathematical, physical, and engineering sciences, 380(2214)

Sandmann FG, Jit M. (2021). Rapid COVID-19 vaccine rollout: immense success but challenges ahead. The Lancet. Infectious diseases

Horváth-Puhó E, van Kassel MN, Gonçalves BP, de Gier B, Procter SR, Paul P, van der Ende A, Søgaard KK, Hahné SJM, Chandna J, Schrag SJ, van de Beek D, Jit M, Sørensen HT, Bijlsma MW, Lawn JE. (2021). Mortality, neurodevelopmental impairments, and economic outcomes after invasive group B streptococcal disease in early infancy in Denmark and the Netherlands: a national matched cohort study. The Lancet. Child & adolescent health

Paul P, Procter SR, Dangor Z, Bassat Q, Abubakar A, Santhanam S, Libster R, Gonçalves BP, Madhi SA, Bardají A, Mwangome E, Mabrouk A, John HB, Sánchez Yanotti C, Chandna J, Sithole P, Mucasse H, Katana PV, Koukounari A, Harden LM, Aerts C, Ghoor A, Leahy S, Mbatha S, Lowick S, Lala SG, Bramugy J, Newton C, Hossain AKMT, Sadeq-Ur Rahman Q, Lambach P, Jit M, Lawn JE. (2021). Quantifying long-term health and economic outcomes for survivors of group B Streptococcus invasive disease in infancy: protocol of a multi-country study in Argentina, India, Kenya, Mozambique and South Africa. Gates open research, (4)

Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M, . (2021). The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. The Lancet. Infectious diseases

Baker JM, Hasso-Agopsowicz M, Pitzer VE, Platts-Mills JA, Peralta-Santos A, Troja C, Archer H, Guo B, Sheahan W, Lingappa J, Jit M, Lopman BA. (2021). Association of enteropathogen detection with diarrhoea by age and high versus low child mortality settings: a systematic review and meta-analysis. The Lancet. Global health, 9(10)

Fu H, Abbas K, Klepac P, van Zandvoort K, Tanvir H, Portnoy A, Jit M. (2021). Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries. BMC medicine, 19(1)

Phua LC, Choi HCW, Wu J, Jit M, Low J, Ng K, Pearce F, Hall C, Abdul Aziz MI. (2021). Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine

Toor J, Echeverria-Londono S, Li X, Abbas K, Carter ED, Clapham HE, Clark A, de Villiers MJ, Eilertson K, Ferrari M, Gamkrelidze I, Hallett TB, Hinsley WR, Hogan D, Huber JH, Jackson ML, Jean K, Jit M, Karachaliou A, Klepac P, Kraay A, Lessler J, Li X, Lopman BA, Mengistu T, Metcalf CJE, Moore SM, Nayagam S, Papadopoulos T, Perkins TA, Portnoy A, Razavi H, Razavi-Shearer D, Resch S, Sanderson C, Sweet S, Tam Y, Tanvir H, Tran Minh Q, Trotter CL, Truelove SA, Vynnycky E, Walker N, Winter A, Woodruff K, Ferguson NM, Gaythorpe KA. (2021). Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife, (10)

Butkeviciute E, Prudden HJ, Jit M, Smith PG, Kang G, Riddle MS, Lopman BA, Pitzer VE, Lanata CF, Platts-Mills JA, Breiman RF, Giersing BK, Hasso-Agopsowicz M. (2021). Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection. Vaccine

Whitworth HS, Schiller J, Markowitz LE, Jit M, Brisson M, Simpson E, Watson-Jones D. (2021). Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine

Yu Q, Li X, Fan M, Qiu H, Wong AYS, Tian L, Chui CSL, Li PH, Lau LKW, Chan EW, Goggins WB, Ip P, Lum TY, Hung IFN, Cowling BJ, Wong ICK, Jit M. (2021). The impact of childhood pneumococcal conjugate vaccine immunisation on all-cause pneumonia admissions in Hong Kong: A 14-year population-based interrupted time series analysis. Vaccine

Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, Jit M. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet

Davies NG, Flasche S, Jit M, Atkins KE. (2021). Modeling the effect of vaccination on selection for antibiotic resistance in Streptococcus pneumonia e. Science translational medicine, 13(606)

Zhou X, Song Y, Jiang H, Wang Q, Qu Z, Zhou X, Jit M, Hou Z, Lin L. (2021). Comparison of public response to containment measures during the initial outbreak and resurgence of COVID-19 epidemic in China: an infodemiology study. Journal of medical Internet research

Yang J, Zheng W, Shi H, Yan X, Dong K, You Q, Zhong G, Gong H, Chen Z, Jit M, Viboud C, Ajelli M, Yu H. (2021). Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC medicine, 19(1)

Tuan LA, Prem K, Pham QD, Toh ZQ, Tran HP, Nguyen PD, Mai CTN, Ly LTK, Cao V, Le-Ha TD, Tuan NA, Jit M, Bright K, Brisson M, Nguyen TV, Garland S, Anh DD, Van Trang N, Mulholland K. (2021). Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Echeverria-Londono S, Li X, Toor J, de Villiers MJ, Nayagam S, Hallett TB, Abbas K, Jit M, Klepac P, Jean K, Garske T, Ferguson NM, Gaythorpe KAM. (2021). How can the public health impact of vaccination be estimated?. BMC public health, 21(1)

Drolet M, Laprise JF, Martin D, Jit M, Bénard É, Gingras G, Boily MC, Alary M, Baussano I, Hutubessy R, Brisson M. (2021). Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. The Lancet. Infectious diseases

Liu Y, Morgenstern C, Kelly J, Lowe R, , Jit M. (2021). The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC medicine, 19(1)

Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van Zandvoort K, Silverman JD, , , Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ. (2021). Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (New York, N.Y.)

Xia C, Xu X, Zhao X, Hu S, Qiao Y, Zhang Y, Hutubessy R, Basu P, Broutet N, Jit M, Zhao F. (2021). Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC medicine, 19(1)

Aerts C, Leahy S, Mucasse H, Lala S, Bramugy J, Tann CJ, Madhi SA, Bardají A, Bassat Q, Dangor Z, Lawn JE, Jit M, Procter SR. (2021). Quantifying the acute care costs of neonatal bacterial sepsis and meningitis in Mozambique and South Africa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Lawn JE, Chandna J, Paul P, Jit M, Trotter C, Lambach P, Ter-Meulen AS. (2021). Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Hodgson D, Flasche S, Jit M, Kucharski AJ, , . (2021). The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 26(20)

Torres-Rueda S, Sweeney S, Bozzani F, Naylor NR, Baker T, Pearson C, Eggo R, Procter SR, Davies N, Quaife M, Kitson N, Keogh-Brown MR, Jensen HT, Saadi N, Khan M, Huda M, Kairu A, Zaidi R, Barasa E, Jit M, Vassall A. (2021). Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries. BMJ global health, 6(12)

Jombart T, Ghozzi S, Schumacher D, Taylor TJ, Leclerc QJ, Jit M, Flasche S, Greaves F, Ward T, Eggo RM, Nightingale E, Meakin S, Brady OJ, , Medley GF, Höhle M, Edmunds WJ. (2021). Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 376(1829)

Portnoy A, Abbas K, Sweet S, Kim JJ, Jit M. (2021). Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study. BMJ global health, 6(11)

Jit M, Ananthakrishnan A, McKee M, Wouters OJ, Beutels P, Teerawattananon Y. (2021). Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. The Lancet regional health. Europe, (9)

Jit M. (2021). Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(1)

Sandmann F, Ramsay M, Edmunds WJ, Choi YH, Jit M. (2021). How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(10)

Sweeney S, Capeding TPJ, Eggo R, Huda M, Jit M, Mudzengi D, Naylor NR, Procter S, Quaife M, Serebryakova L, Torres-Rueda S, Vargas V, , Vassall A. (2021). Exploring equity in health and poverty impacts of control measures for SARS-CoV-2 in six countries. BMJ global health, 6(5)

Gonçalves BP, Procter SR, Clifford S, Koukounari A, Paul P, Lewin A, Jit M, Lawn J. (2021). Estimation of country-level incidence of early-onset invasive Group B Streptococcus disease in infants using Bayesian methods. PLoS computational biology, 17(6)

Forman R, Jit M, Mossialos E. (2021). Divergent vaccination policies could fuel mistrust and hesitancy. Lancet

Barnard RC, Davies NG, , Jit M, Edmunds WJ. (2022). Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. medRxiv : the preprint server for health sciences

Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, Zhang S, Ge M, Pathadka S, Chung CCY, Chung BHY, Chui CSL, Chan EW, Wong GHY, Lum TY, Wong ICK, Ip P, Li X. (2020). Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 23(12)

Sun X, Lin H, Jit M, Li Z, Fu C. (2021). Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network. The Journal of infection

Abbas KM, van Zandvoort K, Brisson M, Jit M. (2020). Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet. Global health

King EM, Mesher D, Sonnenberg P, Linley E, Panwar K, Beddows S, Soldan K, Borrow R, Jit M, Gilson R. (2020). HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sexually transmitted infections

Tam CC, Yeo KT, Tee N, Lin R, Mak TM, Thoon KC, Jit M, Yung CF. (2020). Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerging infectious diseases, 26(7)

Davies NG, Barnard RC, Jarvis CI, Russell TW, Semple MG, Jit M, Edmunds WJ, , . (2020). Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. The Lancet. Infectious diseases

Baral R, Li X, Willem L, Antillon M, Vilajeliu A, Jit M, Beutels P, Pecenka C. (2020). The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models. Vaccine

Quilty BJ, Diamond C, Liu Y, Gibbs H, Russell TW, Jarvis CI, Prem K, Pearson CAB, Clifford S, Flasche S, , Klepac P, Eggo RM, Jit M. (2020). The effect of travel restrictions on the geographical spread of COVID-19 between large cities in China: a modelling study. BMC medicine, 18(1)

Abbas K, Procter SR, van Zandvoort K, Clark A, Funk S, Mengistu T, Hogan D, Dansereau E, Jit M, Flasche S,. (2020). Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. The Lancet. Global health

Sun H, Dickens BL, Jit M, Cook AR, Carrasco LR. (2020). Mapping the cryptic spread of the 2015-2016 global Zika virus epidemic. BMC medicine, 18(1)

Davies NG, Klepac P, Liu Y, Prem K, Jit M, , Eggo RM. (2020). Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature medicine

Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, Sanderson C, McKee M, Troeger C, Ong KL, Checchi F, Perel P, Joseph S, Gibbs HP, Banerjee A, Eggo RM,. (2020). Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet. Global health

Portnoy A, Clark S, Ozawa S, Jit M. (2020). The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study. International journal for equity in health, 19(1)

Yang J, Atkins KE, Feng L, Baguelin M, Wu P, Yan H, Lau EHY, Wu JT, Liu Y, Cowling BJ, Jit M, Yu H. (2020). Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysis. BMC medicine, 18(1)

Forman R, Anderson M, Jit M, Mossialos E. (2020). Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. Vaccine, 38(39)

Jit M, Prem K, Benard E, Brisson M. (2020). From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness. Preventive medicine

Sandmann FG, White PJ, Ramsay M, Jit M. (2020). Optimising benefits of testing key workers for infection with SARS-CoV-2: A mathematical modelling analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Russell TW, Wu JT, Clifford S, Edmunds WJ, Kucharski AJ, Jit M,. (2020). Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. The Lancet. Public health

Tu S, Sun FY, Chantler T, Zhang X, Jit M, Han K, Rodewald L, Du F, Yu H, Hou Z, Larson H. (2020). Caregiver and service provider vaccine confidence following the Changchun Changsheng vaccine incident in China: A cross-sectional mixed methods study. Vaccine

Jit M, Ng DHL, Luangasanatip N, Sandmann F, Atkins KE, Robotham JV, Pouwels KB. (2020). Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC medicine, 18(1)

Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. (2020). Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC medicine, 18(1)

Privor-Dumm LA, Poland GA, Barratt J, Durrheim DN, Deloria Knoll M, Vasudevan P, Jit M, Bonvehí PE, Bonanni P,. (2020). A global agenda for older adult immunization in the COVID-19 era: A roadmap for action. Vaccine

Gilson R, Nugent D, Bennett K, Doré CJ, Murray ML, Meadows J, Haddow LJ, Lacey C, Sandmann F, Jit M, Soldan K, Tetlow M, Caverly E, Nathan M, Copas AJ. (2020). Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. Health technology assessment (Winchester, England), 24(47)

Jit M, Jombart T, Nightingale ES, Endo A, Abbott S, Lshtm Centre For Mathematical Modelling Of Infectious Diseases Covid-Working Group, Edmunds WJ. (2020). Estimating number of cases and spread of coronavirus disease (COVID-19) using critical care admissions, United Kingdom, February to March 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 25(18)

Portnoy A, Jit M, Helleringer S, Verguet S. (2020). Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 23(7)

Ochalek J, Abbas K, Claxton K, Jit M, Lomas J. (2020). Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ global health, 5(10)

Procter SR, Salman O, Pecenka C, Gonçalves BP, Paul P, Hutubessy R, Lambach P, Lawn JE, Jit M. (2020). A review of the costs of delivering maternal immunisation during pregnancy. Vaccine

Luyten J, Kessels R, Atkins KE, Jit M, van Hoek AJ. (2019). Quantifying the public's view on social value judgments in vaccine decision-making: A discrete choice experiment. Social science & medicine (1982), (228)

Knight GM, Davies NG, Colijn C, Coll F, Donker T, Gifford DR, Glover RE, Jit M, Klemm E, Lehtinen S, Lindsay JA, Lipsitch M, Llewelyn MJ, Mateus ALP, Robotham JV, Sharland M, Stekel D, Yakob L, Atkins KE. (2019). Mathematical modelling for antibiotic resistance control policy: do we know enough?. BMC infectious diseases, 19(1)

Jit M, Flasche S. (2019). The role of pneumococcal conjugate vaccination in reducing pneumonia mortality. The Lancet. Global health, 7(2)

Portnoy A, Jit M, Ferrari M, Hanson M, Brenzel L, Verguet S. (2019). Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. The Lancet. Global health, 7(4)

Bains I, Choi YH, Soldan K, Jit M. (2019). Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Clark A, Tate J, Parashar U, Jit M, Hasso-Agopsowicz M, Henschke N, Lopman B, Van Zandvoort K, Pecenka C, Fine P, Sanderson C. (2019). Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. The Lancet. Global health, 7(11)

Davies NG, Flasche S, Jit M, Atkins KE. (2019). Within-host dynamics shape antibiotic resistance in commensal bacteria. Nature ecology & evolution, 3(3)

Takwoingi Y, Whitworth H, Rees-Roberts M, Badhan A, Partlett C, Green N, Boakye A, Lambie H, Marongiu L, Jit M, White P, Deeks JJ, Kon OM, Lalvani A. (2019). Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation. Health technology assessment (Winchester, England), 23(23)

Sim SY, Jit M, Constenla D, Peters DH, Hutubessy RCW. (2019). A Scoping Review of Investment Cases for Vaccines and Immunization Programs. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 22(8)

Markowitz LE, Drolet M, Perez N, Jit M, Brisson M. (2018). Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine, 36(32 Pt A)

Howard N, Bell S, Walls H, Blanchard L, Brenzel L, Jit M, Mounier-Jack S. (2018). The need for sustainability and alignment of future support for National Immunization Technical Advisory Groups (NITAGs) in low and middle-income countries. Human vaccines & immunotherapeutics, 14(6)

Jit M, Brisson M. (2018). Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14-year-old girls against human papillomavirus. International journal of cancer, 143(2)

Sandmann FG, Shallcross L, Adams N, Allen DJ, Coen PG, Jeanes A, Kozlakidis Z, Larkin L, Wurie F, Robotham JV, Jit M, Deeny SR. (2018). Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 67(5)

Bate J, Baker S, Breuer J, Chisholm JC, Gray J, Hambleton S, Houlton A, Jit M, Lowis S, Makin G, O'Sullivan C, Patel SR, Phillips R, Ransinghe N, Ramsay ME, Skinner R, Wheatley K, Heath PT. (2019). PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer. Archives of disease in childhood, 104(1)

Murray ML, Meadows J, Doré CJ, Copas AJ, Haddow LJ, Lacey C, Jit M, Soldan K, Bennett K, Tetlow M, Nathan M, Gilson R. (2018). Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC medical research methodology, 18(1)

Bissett SL, Godi A, Jit M, Beddows S. (2017). Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine, 35(32)

Atkins KE, Lafferty EI, Deeny SR, Davies NG, Robotham JV, Jit M. (2018). Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. The Lancet. Infectious diseases, 18(6)

Van Minh H, My NTT, Jit M. (2017). Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC health services research, 17(1)

Sandmann FG, Robotham JV, Deeny SR, Edmunds WJ, Jit M. (2018). Estimating the opportunity costs of bed-days. Health economics, 27(3)

Wong JJ, Jit M, Sultana R, Mok YH, Yeo JG, Koh JWJC, Loh TF, Lee JH. (2019). Mortality in Pediatric Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Journal of intensive care medicine, 34(7)

Ng D, Ghosh A, Jit M, Seneviratne SL. (2017). Mini-review: Can non-human leucocyte antigen genes determine susceptibility to severe dengue syndromes?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 111(9)

Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. (2017). Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. The Lancet. Public health, 2(8)

Recker M, Vannice K, Hombach J, Jit M, Simmons CP. (2016). Assessing dengue vaccination impact: Model challenges and future directions. Vaccine, 34(38)

Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M. (2017). Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 64(5)

Loganathan T, Ng CW, Lee WS, Jit M. (2016). The Hidden Health and Economic Burden of Rotavirus Gastroenteritis in Malaysia: An Estimation Using Multiple Data Sources. The Pediatric infectious disease journal, 35(6)

Jit M. (2016). The economic burden of dengue: no longer invisible or unavoidable. The Lancet. Infectious diseases, 16(8)

Atkins K, van Hoek AJ, Watson C, Baguelin M, Choga L, Patel A, Raj T, Jit M, Griffiths U. (2016). Seasonal influenza vaccination delivery through community pharmacists in England: evaluation of the London pilot. BMJ open, 6(2)

Ong KJ, Soldan K, Jit M, Dunbar JK, Woodhall SC. (2017). Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?. Sexually transmitted infections, 93(1)

King EM, Oomeer S, Gilson R, Copas A, Beddows S, Soldan K, Jit M, Edmunds WJ, Sonnenberg P. (2016). Oral Human Papillomavirus Infection in Men Who Have Sex with Men: A Systematic Review and Meta-Analysis. PloS one, 11(7)

Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, Milne G, Hladish TJ, Perkins TA, Cummings DA, Dorigatti I, Laydon DJ, España G, Kelso J, Longini I, Lourenco J, Pearson CA, Reiner RC, Mier-Y-Terán-Romero L, Vannice K, Ferguson N. (2016). The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS medicine, 13(11)

Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, de Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C. (2016). Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. The Lancet. Public health, 1(1)

Wu JT, Jit M, Zheng Y, Leung K, Xing W, Yang J, Liao Q, Cowling BJ, Yang B, Lau EH, Takahashi S, Farrar JJ, Grenfell BT, Leung GM, Yu H. (2016). Correction: Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. PLoS medicine, 13(4)

Jit M, Dang TT, Friberg I, Hoang VM, Pham Huy TK, Walker N, Nguyen VC, Tran ND, Toda K, Hutubessy R, Fox K, Nguyen TH. (2015). Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization. Vaccine, (33 Suppl 1)

Portnoy A, Jit M, Lauer J, Blommaert A, Ozawa S, Stack M, Murray J, Hutubessy R. (2015). Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, (33 Suppl 1)

Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. (2016). Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. PharmacoEconomics, 34(3)

Jit M. (2015). High-dose influenza vaccines make economic sense for older people. The Lancet. Infectious diseases, 15(12)

Jit M, Franco E, Jha P. (2015). What makes an eLife paper in epidemiology and global health?. eLife, (4)

Jit M, Brisson M, Laprise JF, Choi YH. (2015). Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ (Clinical research ed.), (350)

Mendes D, Bains I, Vanni T, Jit M. (2015). Systematic review of model-based cervical screening evaluations. BMC cancer, (15)

Verguet S, Johri M, Morris SK, Gauvreau CL, Jha P, Jit M. (2015). Controlling measles using supplemental immunization activities: a mathematical model to inform optimal policy. Vaccine, 33(10)

Quinn E, Jit M, Newall AT. (2014). Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert review of pharmacoeconomics & outcomes research, 14(3)

Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. (2014). Two-dose strategies for human papillomavirus vaccination: how well do they need to protect?. Vaccine, 32(26)

Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Mölstad S, Coast J. (2013). Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. The British journal of general practice : the journal of the Royal College of General Practitioners, 63(612)

Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. (2012). Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet. Infectious diseases, 12(10)

Baguelin M, Jit M, Miller E, Edmunds WJ. (2012). Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine, 30(23)

van Hoek AJ, Choi YH, Trotter C, Miller E, Jit M. (2012). The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine, 30(50)

Newall AT, Jit M, Beutels P. (2012). Economic evaluations of childhood influenza vaccination: a critical review. PharmacoEconomics, 30(8)

Choi YH, Jit M, Flasche S, Gay N, Miller E. (2012). Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PloS one, 7(7)

Choi YH, Chapman R, Gay N, Jit M. (2012). Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine, 30(23)

Jit M, Chapman R, Hughes O, Choi YH. (2011). Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (Clinical research ed.), (343)

Chapman R, Soldan K, Jit M. (2011). Modelling borderline and mild dysplasia associated with HPV 6 and 11 infection. Vaccine, 29(16)

Jit M, Brisson M. (2011). Modelling the epidemiology of infectious diseases for decision analysis: a primer. PharmacoEconomics, 29(5)

Jit M, Demarteau N, Elbasha E, Ginsberg G, Kim J, Praditsitthikorn N, Sinanovic E, Hutubessy R. (2011). Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC medicine, (9)

Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. (2010). Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine, 28(24)

Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P. (2009). The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine, 27(44)

Jit M, Pebody R, Chen M, Andrews N, Edmunds WJ. (2007). Estimating the number of deaths with rotavirus as a cause in England and wales. Human vaccines, 3(1)

If you’d like to update your profile, please email modifications to questions@midasnetwork.us.

This site is registered on wpml.org as a development site.